PARP7 is a mono-ADP-ribosyl transferase (mono-ART) which has recently gained attention due to its emerging role as a negative ...
Clinical Trials Arena on MSN5d
FDA aligns with Imunon’s Phase III trial protocol for ovarian cancer treatmentImunon is initiating sites for the trial and collaborating with investigators to commence participant enrolment.
Measuring cellular poly ADP-ribosylation can unlock new anticancer strategies and approaches. ADP-ribosylation, the attachment of ADP-ribose to proteins, is a common eukaryotic post-translational ...
DelveInsight’s, “Colorectal Cancer Pipeline Insight 2025” report provides comprehensive insights about 195+ companies and ...
The phase 3 trial design evaluating IMNN-001 in newly diagnosed advanced ovarian cancer has been finalized among regulatory ...
IMUNON (IMNN) announced that the U.S. Food and Drug Administration is aligned with the protocol for the Phase 3 pivotal trial, called OVATION ...
Recent work in The EMBO Journal describes a new hybrid post-translational modification of proteins, composed of a poly-ubiquitin chain that is attached to a target protein via a mono-ADP-ribose (MAR) ...
Regulation of cellular levels of ADP-ribose is important in preventing nonenzymatic ADP-ribosylation of proteins. The Escherichia coli ADP-ribose pyrophosphatase, a Nudix enzyme, catalyzes the ...
These cancers are, however, quite sensitive to anticancer drugs such as poly (ADP-ribose) polymerase inhibitors (PARPi). When successful, these cancer treatments cause enough DNA damage to trigger ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback